MyFinsight
Home
Blog
About
INSMED Inc (INSM)
INSMED Inc (INSM)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$37,423K
Free Cash flow
-$95,087K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Change in fair value of continge...
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Other segment items
Change in fair value of continge...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product revenues, net
425,486
-36,616
-
342,580
Cost of product revenues (excluding amortization of intangible assets)
67,212
-31,298
-
78,718
Research and development-TPIP
38,935
-21,215
-
58,556
Research and development-Brensocatib
13,829
-55,092
-
73,576
Research and development-ARIKAYCE
6,228
-23,716
-
32,338
Research and development-Other
48,836
-60,429
-
93,107
R&d compensation and benefit-related expenses
69,080
-101,624
-
173,764
Sg&a compensation and benefit-related expenses
70,520
-93,650
-
168,443
Other segment items
207,425
-187,787
-
398,275
Depreciation
3,179
-3,891
-
6,825
Amortization of intangible assets
2,081
-1,983
-
4,064
Change in fair value of contingent consideration
-99,760
-228,914
-
181,953
Investment income
10,979
-33,380
-
45,420
Interest expense
20,273
-43,114
-
63,196
Provision for income taxes
1,869
-2,010
-
3,475
Net loss
-13,242
-163,563
-328,485
-370,021
Depreciation
3,179
2,934
3,624
2,458
Amortization of intangible assets
2,081
2,081
1,937
1,538
Stock-based compensation expense
41,254
45,754
39,039
31,433
Amortization of debt issuance costs
1,429
1,382
1,376
1,342
Paid-in-kind interest capitalized
-
-
0
0
Royalty financing non-cash interest expense
5,129
5,114
5,331
5,129
Accretion of discount on marketable securities, net
5,464
6,513
10,397
12,041
Finance lease amortization expense
678
678
678
678
Non-cash operating lease expense
819
567
6,904
1,174
Change in fair value of contingent consideration
-99,760
-46,961
70,040
104,653
Change in fair value of interest rate swap
-
-
0
0
Vertuis/adrestia acquisition-Vertuis Bio Inc
-
-
0
-
Vertuis/adrestia acquisition-Adrestia Therapeutics Ltd
-
-
0
-
Accounts receivable
37,160
38,190
77,300
10,226
Inventory
12,974
1,886
11,764
13,758
Prepaid expenses and other current assets
37,643
-12,594
26,224
3,732
Other assets
5,230
2,357
11,787
2,851
Accounts payable and accrued liabilities
68,820
-33,875
90,346
45,559
Other liabilities
-744
-497
-914
-1,096
Net cash used in operating activities
-88,828
-222,738
-247,596
-219,761
Purchase of fixed assets
6,259
3,480
16,589
2,418
Payment of az milestone
0
15,000
30,000
-
Purchase of marketable securities
399,228
0
0
1,184,815
Cash acquired in asset acquisition
-
-
0
-
Maturities of marketable securities
430,000
284,000
436,000
425,000
Net cash provided by investing activities
24,513
265,520
389,411
-762,233
Proceeds from exercise of stock options and espp
28,006
30,313
34,635
34,413
Proceeds from issuance of common stock, net
0
-
0
-256
Proceeds from issuance of term loan
-
-
0
-
Payments of principal of 0.75 convertible senior notes due 2028
0
-
0
0
Payment of debt issuance costs
-
-
0
-
Payments of finance lease principal
827
799
776
747
Net cash provided by financing activities
27,179
29,514
33,859
33,410
Effect of exchange rates on cash and cash equivalents
-287
-553
7
-976
Net increase in cash and cash equivalents
-37,423
71,743
175,681
-949,560
Cash and cash equivalents at beginning of period
582,188
510,445
403,247
403,247
Cash and cash equivalents at end of period
544,765
582,188
510,445
334,764
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options and espp
$28,006K
(-24.24%↓ Y/Y)
Maturities of marketable
securities
$430,000K
(-15.35%↓ Y/Y)
Net cash provided by
financing activities
$27,179K
(-96.83%↓ Y/Y)
Net cash provided by
investing activities
$24,513K
(-89.24%↓ Y/Y)
Canceled cashflow
$827K
Canceled cashflow
$405,487K
Net increase in cash
and cash...
-$37,423K
(-104.25%↓ Y/Y)
Canceled cashflow
$51,692K
Accounts payable and
accrued liabilities
$68,820K
(168.22%↑ Y/Y)
Stock-based compensation
expense
$41,254K
(-4.01%↓ Y/Y)
Royalty financing
non-cash interest...
$5,129K
(-1.21%↓ Y/Y)
Depreciation
$3,179K
(27.98%↑ Y/Y)
Amortization of intangible
assets
$2,081K
(64.77%↑ Y/Y)
Amortization of debt issuance
costs
$1,429K
(-14.74%↓ Y/Y)
Non-cash operating lease
expense
$819K
(-7.77%↓ Y/Y)
Finance lease
amortization expense
$678K
(0.00%↑ Y/Y)
Payments of finance lease
principal
$827K
(12.98%↑ Y/Y)
Purchase of marketable
securities
$399,228K
(44.29%↑ Y/Y)
Purchase of fixed assets
$6,259K
(79.65%↑ Y/Y)
Net cash used in
operating activities
-$88,828K
(56.79%↑ Y/Y)
Canceled cashflow
$123,389K
Effect of exchange
rates on cash and cash...
-$287K
(-128.56%↓ Y/Y)
Product revenues, net
$425,486K
Change in fair value of
contingent consideration
-$99,760K
Investment income
$10,979K
Change in fair value of
contingent consideration
-$99,760K
(-269.08%↓ Y/Y)
Prepaid expenses and
other current assets
$37,643K
(476.11%↑ Y/Y)
Accounts receivable
$37,160K
(505.01%↑ Y/Y)
Net loss
-$13,242K
(95.88%↑ Y/Y)
Inventory
$12,974K
(160.73%↑ Y/Y)
Accretion of discount on
marketable securities, net
$5,464K
(-27.90%↓ Y/Y)
Other assets
$5,230K
(322.84%↑ Y/Y)
Other liabilities
-$744K
(8.71%↑ Y/Y)
Canceled cashflow
$536,225K
Other segment items
$207,425K
Sg&a compensation
and...
$70,520K
R&d compensation
and...
$69,080K
Cost of product
revenues (excluding...
$67,212K
Research and
development-Other
$48,836K
Research and
development-TPIP
$38,935K
Interest expense
$20,273K
Research and
development-Brensocatib
$13,829K
Research and
development-ARIKAYCE
$6,228K
Depreciation
$3,179K
(27.98%↑ Y/Y)
Amortization of intangible
assets
$2,081K
(64.77%↑ Y/Y)
Provision for income taxes
$1,869K
Buy us a coffee
🚨
Price Alert:
The stock price jumped by 28.54% after the earning call.